Changing The Subject (Part 1): Stop Trying To “Win” The Drug Pricing Debate
This article was originally published in RPM Report
Executive Summary
When it comes to pricing, it is worth remembering that the interests of buyers and sellers can never be truly aligned. So rather than trying to “win” the drug pricing debate, the pharmaceutical industry may be better served by steering it into new areas. We plan to propose some big ideas that might work in that direction.
You may also be interested in...
Smart Segmentation: Success In The Payer-Dominated Pharma Marketplace
As physicians lose decision-making authority to payers, argues Roger Longman of Real Endpoints, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs' use.
Changing the Subject (Part 2): Turning Turing Around By Offering A “National Center Of Pharmaceutical Supply”
Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. We outlined our case for taking this approach – and the model for ideas that serve that goal – here
. Now we offer the first proposal: a national center for off-patent pharmaceutical production.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.